Barclays Boosts Danaher (NYSE:DHR) Price Target to $285.00

Danaher (NYSE:DHR) had its target price upped by Barclays from $270.00 to $285.00 in a research report report published on Wednesday, Benzinga reports. They currently have an equal weight rating on the conglomerate’s stock.

DHR has been the topic of a number of other research reports. HSBC upgraded shares of Danaher from a hold rating to a buy rating and lifted their price target for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. The Goldman Sachs Group boosted their price target on Danaher from $225.00 to $250.00 and gave the company a neutral rating in a research report on Wednesday. StockNews.com downgraded Danaher from a buy rating to a hold rating in a report on Tuesday, June 25th. Evercore ISI reduced their price objective on Danaher from $266.00 to $260.00 and set an outperform rating on the stock in a research note on Tuesday, July 2nd. Finally, Stifel Nicolaus increased their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a hold rating in a research report on Wednesday. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, Danaher has an average rating of Moderate Buy and a consensus target price of $276.88.

Danaher Price Performance

DHR stock opened at $274.13 on Wednesday. The stock has a market capitalization of $197.98 billion, a price-to-earnings ratio of 46.46, a price-to-earnings-growth ratio of 4.11 and a beta of 0.83. The company has a quick ratio of 1.51, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher has a 52-week low of $182.09 and a 52-week high of $277.72. The stock’s fifty day simple moving average is $255.16 and its 200-day simple moving average is $249.09.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the company earned $2.05 EPS. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. Equities research analysts expect that Danaher will post 7.6 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, July 26th. Investors of record on Friday, June 28th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend was Friday, June 28th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Activity at Danaher

In other Danaher news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 84,775 shares of company stock valued at $21,802,690. Insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in DHR. Patrick M Sweeney & Associates Inc. boosted its holdings in Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after purchasing an additional 40 shares during the period. Trust Co of Kansas boosted its holdings in shares of Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after buying an additional 40 shares during the period. ST Germain D J Co. Inc. grew its position in shares of Danaher by 1.4% during the 1st quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after buying an additional 41 shares during the last quarter. Godsey & Gibb Inc. raised its stake in Danaher by 3.0% during the first quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock worth $360,000 after acquiring an additional 42 shares during the period. Finally, Premier Path Wealth Partners LLC lifted its holdings in Danaher by 1.8% in the second quarter. Premier Path Wealth Partners LLC now owns 2,345 shares of the conglomerate’s stock worth $586,000 after acquiring an additional 42 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.